Point-of-Care Microchip Electrophoresis Test for Glycosylated Hemoglobin

Diabetes is responsible for 4.6 million deaths worldwide each year, and the prevalence of diabetes is expected to rise to 552 million by 2030. Diabetes is not only a leading cause of morbidity and mortality, but its complications also impose a large financial burden on patients and their families. Diabetes outcomes can be improved by early detection and monitoring. However, accurate diabetes diagnosis and monitoring remain a challenge, particularly in low- and middle-income nations. Here, we present a new microchip electrophoresis approach and point-of-care (POC) technology platform to feasibly detect and quantify glycosylated hemoglobin.Clinical Relevance—We present a novel microchip electrophoresis point-of-care test for diagnosis and monitoring of diabetes.